Publication | Closed Access

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer

OncologyMedicineGynecologyParp Inhibitor ResponseAnti-cancer AgentCancer TreatmentPharmacologyPatient-derived OrganoidsEndocrine-related CancerOvarian Cancer